Editorial: Food for Thought—Addressing the Nuances of Diet and Mood When Evaluating Dietary Intervention in IBS. Authors' Reply

IF 6.6 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Alimentary Pharmacology & Therapeutics Pub Date : 2024-11-07 DOI:10.1111/apt.18384
Anthony O'Connor, Sarah Gill, Elaine Neary, Sarah White, Alexander C. Ford
{"title":"Editorial: Food for Thought—Addressing the Nuances of Diet and Mood When Evaluating Dietary Intervention in IBS. Authors' Reply","authors":"Anthony O'Connor,&nbsp;Sarah Gill,&nbsp;Elaine Neary,&nbsp;Sarah White,&nbsp;Alexander C. Ford","doi":"10.1111/apt.18384","DOIUrl":null,"url":null,"abstract":"<p>We thank Drs Katzenstein and Keefer for their editorial on our paper [<span>1, 2</span>]. We fully agree on the need for progress towards an integrated, personalised model of care for patients with disorders of gut-brain interaction. We are aware of the limitations of the Hospital Anxiety and Depression Scale (HADS) and concur that it does not capture all the psychological nuances seen in patients with irritable bowel syndrome (IBS). However, it is easily understood and administered by non-specialist practitioners and has been used across a range of DGBIs by others [<span>3</span>]. Although the imperative for the development of symptom-specific questionnaires, specific psychosocial questionnaires and inclusion of psychosocial well-being have been championed by expert opinion, none was in use at the time of our study, and none has since emerged [<span>4</span>].</p><p>As the study was conducted in routine clinical practice and at the time of the Coronavirus pandemic, many patients were consulted with remotely. We believed it would have been difficult to repeat the HADS post-intervention. In addition, around the time of lockdown restrictions related to the pandemic, observed incidences of anxiety and depression were increased [<span>5</span>]. In such a setting, to infer that any changes observed in HADS over the period of the intervention were due to dietary therapy or IBS symptom status alone may have been an over-simplification.</p><p>The vast majority of patients with IBS are, and will continue to be, treated in primary and secondary care by either generalist physicians and dietitians or others with a subspeciality interest in the field. We, therefore, contend that the design and findings of our study are broadly generalisable to existing models of care and show promising results even in patients with more severe symptoms, overlapping symptomatology and poor psychological health, which will resonate with clinical practitioners across disciplines. Like Drs Katzenstein and Keefer, we look forward to the type of studies that will lead to greater comprehension of the intersection of food and mood, and to uncover the underlying mechanisms at play. Until then, evidence from studies such as our own—that may improve understanding of how psychological parameters could predict response to commonly used interventions—is an important step towards personalising care for patients with IBS.</p><p><b>Anthony O'Connor:</b> conceptualization, investigation, writing – original draft, methodology, writing – review and editing, visualization, validation, formal analysis, data curation, project administration. <b>Sarah Gill:</b> conceptualization, investigation, methodology, validation, formal analysis, data curation. <b>Elaine Neary:</b> conceptualization, investigation, methodology, validation, data curation. <b>Sarah White:</b> conceptualization, investigation, methodology, formal analysis. <b>Alexander C. Ford:</b> writing – original draft, writing – review and editing, formal analysis, supervision.</p><p>This article is linked to O’Connor et al papers. To view these articles, visit https://doi.org/10.1111/apt.18337 and https://doi.org/10.1111/apt.18372.</p>","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"61 1","pages":"200-201"},"PeriodicalIF":6.6000,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/apt.18384","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alimentary Pharmacology & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/apt.18384","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

We thank Drs Katzenstein and Keefer for their editorial on our paper [1, 2]. We fully agree on the need for progress towards an integrated, personalised model of care for patients with disorders of gut-brain interaction. We are aware of the limitations of the Hospital Anxiety and Depression Scale (HADS) and concur that it does not capture all the psychological nuances seen in patients with irritable bowel syndrome (IBS). However, it is easily understood and administered by non-specialist practitioners and has been used across a range of DGBIs by others [3]. Although the imperative for the development of symptom-specific questionnaires, specific psychosocial questionnaires and inclusion of psychosocial well-being have been championed by expert opinion, none was in use at the time of our study, and none has since emerged [4].

As the study was conducted in routine clinical practice and at the time of the Coronavirus pandemic, many patients were consulted with remotely. We believed it would have been difficult to repeat the HADS post-intervention. In addition, around the time of lockdown restrictions related to the pandemic, observed incidences of anxiety and depression were increased [5]. In such a setting, to infer that any changes observed in HADS over the period of the intervention were due to dietary therapy or IBS symptom status alone may have been an over-simplification.

The vast majority of patients with IBS are, and will continue to be, treated in primary and secondary care by either generalist physicians and dietitians or others with a subspeciality interest in the field. We, therefore, contend that the design and findings of our study are broadly generalisable to existing models of care and show promising results even in patients with more severe symptoms, overlapping symptomatology and poor psychological health, which will resonate with clinical practitioners across disciplines. Like Drs Katzenstein and Keefer, we look forward to the type of studies that will lead to greater comprehension of the intersection of food and mood, and to uncover the underlying mechanisms at play. Until then, evidence from studies such as our own—that may improve understanding of how psychological parameters could predict response to commonly used interventions—is an important step towards personalising care for patients with IBS.

Anthony O'Connor: conceptualization, investigation, writing – original draft, methodology, writing – review and editing, visualization, validation, formal analysis, data curation, project administration. Sarah Gill: conceptualization, investigation, methodology, validation, formal analysis, data curation. Elaine Neary: conceptualization, investigation, methodology, validation, data curation. Sarah White: conceptualization, investigation, methodology, formal analysis. Alexander C. Ford: writing – original draft, writing – review and editing, formal analysis, supervision.

This article is linked to O’Connor et al papers. To view these articles, visit https://doi.org/10.1111/apt.18337 and https://doi.org/10.1111/apt.18372.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
社论:思考的食物--在评估肠易激综合征的饮食干预时解决饮食与情绪的细微差别。作者回复。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
15.60
自引率
7.90%
发文量
527
审稿时长
3-6 weeks
期刊介绍: Alimentary Pharmacology & Therapeutics is a global pharmacology journal focused on the impact of drugs on the human gastrointestinal and hepato-biliary systems. It covers a diverse range of topics, often with immediate clinical relevance to its readership.
期刊最新文献
Clinical Trial: The Effects of Emulsifiers in the Food Supply on Disease Activity in Crohn's Disease: An Exploratory Double‐Blinded Randomised Feeding Trial Addressing the High and Rising Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction‐Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors' Perspective Comparison Between Dynamic Models for Predicting Response to Corticosteroids in Alcohol‐Associated Hepatitis: A Global Cohort Study Air Pollution Associated With Mortality Among Chronic Hepatitis B Patients Treated With Nucleotide/Nucleoside Analogues. Letter: Lubiprostone—A Novel Therapeutic Avenue for Gastrointestinal Complications in MASLD
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1